Blogs

The Canadian Insider blog discusses news and insight found among executive and significant shareholder filings in Canada.

Follow Nicholas Winton who runs gohht.com for market insight and great stock ideas.

Follow the smart money in the mining industry with the Power Prospectors blog.

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Watch or download Jody Wilson-Raybould's explosive SNC Lavalin affair testimony

Listen to former Attorney General of Canada Jody Wilson-Raybould detail attempts by Justin Trudeau and others to get her to secure a deferred prosecution agreement with SNC Lavalin (SNC). Watch the explosive testimony below.

Watch Canada's former Attorney General drop bombshell-after-bombshell

 

You can also download an audio MP3 version below.

Upbeat Canadian insiders

Starting in the second segment of his latest interview with Jim Goddard, INK CEO Ted Dixon gives an overview of the outlook for Canadian stocks drawing on the most recent Insights weekly newsletter. Broadly speaking, insiders remain upbeat about their prospects going forward, particularly in the oil patch where stocks have undergone a correction to reflect commodity pricing troubles.

He does, however, highlight a warning sign.

INK Canadian Insider Index rises again, but resistance looms above

Thank you for joining us in a weekly technical look at the mid-cap oriented INK Canadian Insider (CIN) Index. Last week, the Index tacked on another 9.1 points to end at 1153.11 for a gain of 0.7%. Over the last 2 weeks, it has climbed 3%.

Insights: Monetary policy winds change direction to favour Canadian stocks

We have just published our second edition of Canadian Insider Insights, a newsletter exclusively for CanadianInsider.com users. This publication seeks to provide a quick read on what insiders are telling us about the outlook for the Canadian market. Commentary draws heavily from our institutional Market INK report to bring you distinct, independent insight you will not find anywhere else.

 

INK's Insider of the week

You can read this week's edition Monetary policy winds change direction to favour Canadian stocks in HTML format via our Insights archive page.

INK Canadian Insider Index finally bursts through 1130, rallies 2.3%

Thank you for joining us in a weekly technical look at the mid-cap oriented INK Canadian Insider (CIN) Index. Last week, the Index continued its impressive New Year's ascent after finally breaking through an overhead wall of resistance at 1130. The Index closed the week at 1143.97 with a gain of 25.7 points or 2.3%.

INK Canadian Insider Index holds steady, eyes rising copper

Thank you for joining us in a weekly technical look at the mid-cap oriented INK Canadian Insider (CIN) Index. Last week, was a fairly quiet week for the Index. It did try to break through the 1127-1130 level but was turned back three times before closing down a nominal 2.5 points at 1118.27.

Madness: Central banks believing they can manage the economy

In his latest Howe Street broadcast, Bob Hoye from ChartsandMarkets.com takes aim at the assumption that the Bank of Canada can control the economy and explains why gold miners and explorers can thrive during a post-bubble contraction.

Myth the Bank of Canada can manage the economy (pic source D. Neuman)

Hoye takes aim at the idea that the central bank keep the economy on track by setting interest rates. In particular, he points out to history that debunks the myth that central banking can prevent economic setbacks.

Ahead of earnings, Bombardier says a senior executive is quitting

A week before Bombardier (No outlook; BBD.B) is scheduled to release its Q4 earnings report on February 14th, the taxpayer supported aerospace, rail & defense firm announced today that it is losing one of its key executives. According to a company press release, Bombardier Transportation President Laurent Troger has informed the company of his intention to resign and pursue opportunities outside the company.

INK Canadian Insider Index rallies 1.9% to new 5-week high

Thank you for joining us in a weekly technical look at the mid-cap oriented INK Canadian Insider (CIN) Index. Last week, the INK Canadian Insider Index began with some heaviness, slipping to the low 1070s where it held above its middle Bollinger band. From there, the INK CIN bounded straight up and through 1100 resistance and came to rest at 1120.75 for a gain of 23.3 points or 1.9%, The Index has now rallied 13.5% from its late December lows.

IMV provides another update this morning on its DPX-Survivac program

After publication of the INK Morning Report this morning, IMV (IMV) released an update on its DPX-Survivac Program following a routine meeting with the FDA.

In the release the company reports:

the FDA acknowledged the potential for accelerated approvals in advanced ovarian cancer based on objective response rate (ORR) according to RECIST 1.1 criteria with reported median duration of response (DOR). In addition, the FDA provided important guidance on clinical design considerations for different lines of therapy and platinum-sensitive and -resistant patient populations.

Tags:

Pages

Subscribe to RSS - blogs